论文部分内容阅读
目的:探讨血清胱抑素C(cystatin C,Cys C)在肿瘤化疗患者肾脏功能评价中的临床应用。方法:随机取37例肿瘤化疗患者和30例正常对照血清,同时测定血清中的Cys C、肌酐(Scr),Cys C检测采用增强透射免疫比浊法;Scr采用苦味酸法测定,并测定患者24 h尿肌酐(Ucr),计算出内生肌酐清除率(Ccr)。结果:肿瘤化疗患者Cys C水平(1.16±0.43)mg/L显著高于正常对照组(0.61±0.06)mg/L;化疗前、后(1个疗程)Cys C、Scr和Ccr水平存在显著性差异(P<0.05);患者化疗前后Cys C的异常检出率均显著高于Scr、Ccr(P<0.05)。结论:Cys C是评价肿瘤患者化疗期间肾功能损伤的一项灵敏、可靠的指标,在反映肿瘤化疗患者肾功能早期损害中有很好的临床参考价值。
Objective: To investigate the clinical application of serum cystatin C (Cys C) in the evaluation of renal function in patients undergoing chemotherapy. Methods: Thirty-seven patients with tumor chemotherapy and 30 normal controls were selected randomly. Serum Cys C and creatinine (Scr) were measured at the same time. Enhanced transfusion immunonephelometry was used to detect Cys C. Scr was determined by picric acid method. 24 h urine creatinine (Ucr), calculated creatinine clearance (Ccr). Results: The level of Cys C (1.16 ± 0.43) mg / L was significantly higher in patients with tumor chemotherapy than that in the normal control group (0.61 ± 0.06) mg / L. There were significant differences in Cys C, Scr and Ccr levels before and after chemotherapy (P <0.05). The abnormal detection rate of Cys C in patients before and after chemotherapy was significantly higher than that of Scr and Ccr (P <0.05). CONCLUSION: Cys C is a sensitive and reliable indicator for assessing renal dysfunction during chemotherapy in cancer patients. It has good clinical value in reflecting the early renal damage in patients with tumor chemotherapy.